Live Breaking News & Updates on A Cell Rejuvenation Company Developing Novel Mrna Medicines To Cure Untreatable

Vittorio Sebastiano, globally recognized for pioneering science, expands his role at company he co-founded as it moves closer to clinical research MOUNTAIN VIEW, Calif., Aug. 8, 2022 /PRNewswire/ Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that co-founder Vittorio Sebastiano, PhD, will become its head of research. Sebastiano led development of the unique mRNA-based ERA (Epigenetic Reprogramming of Aging) platform Turn Bio uses to produce tailored protein cocktails to rejuvenate targeted cells. He assumes his role as head of research this month. Sebastiano has served as chairman of Turn Bio's Scientific Advisory Board since he co-founded the company in 2018. A Stanford School of Medicine faculty member, author of more than 50 scientific articles and frequent speaker at research conferences around the world, Sebastiano is prominent in the emerging field of cellular reprogramming. His ....

United States , Vittorio Sebastiano , Jim Martinez , Anja Krammer , A Stanford School Of Medicine , His Stanford University , American Federation For Aging Research , Glenn Foundation , Stanford Institute For Stem Cell Biology , Max Planck Institute For Molecular Biomedicine , Stanford Stem Cell Phd Program , Epigenetic Reprogramming , Turn Bio , Scientific Advisory Board , Stanford School , Stanford University , Max Planck Institute , Molecular Biomedicine , Stanford Institute , Stem Cell , Woods Family Scholar , Pediatric Medicine , Aging Research , Junior Investigator Award , Gerontology Award , Lobally Recognized For Pioneering Science ,